Technical analysis of Belite Bio, Inc (BLTE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Price Performance
| 1 month | +4.08% |
| 3 months | +15.80% |
| Year-to-date | +5.78% |
| 1 year | +131.79% |
| 3 years | +437.86% |
52-Week Range
| 52-week High | $200.00 |
| 52-week Low | $64.80 |
| Avg Volume (90d) | 205K |
Technical Indicators
| SMA 50 | $161.79 |
| SMA 200 | $159.73 |
| Beta | -1.22 |
| 30-day Volatility (annualised) | 59.3% |
| Price vs SMA 50 | +4.6% |
| Price vs SMA 200 | +5.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $105.91 | |
| 2025-11 | $137.44 | +29.8% |
| 2025-12 | $159.96 | +16.4% |
| 2026-01 | $169.00 | +5.7% |
| 2026-02 | $190.30 | +12.6% |
| 2026-03 | $159.44 | -16.2% |
| 2026-04 | $159.16 | -0.2% |
| 2026-05 | $144.18 | -9.4% |
| 2026-06 | $153.99 | +6.8% |
| 2026-07 | $158.61 | +3.0% |
| 2026-08 | $155.71 | -1.8% |
| 2026-09 | $169.21 | +8.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $0.10 | $84M |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | $0.03 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | $-0.26 | $14M |
Price
| Price | $169.21 |
| Market Cap | $6.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.75 |
| EV / EBITDA | -64.97 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 33.56 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 319.70 |